Soleno Therapeutics Files Material Definitive Agreement
Ticker: SLNO · Form: 8-K · Filed: 2026-04-06T07:46:57-04:00
Sentiment: neutral
Topics: material-agreement, 8-k
TL;DR
SOLENO just filed a material definitive agreement - big news incoming.
AI Summary
On April 6, 2026, Soleno Therapeutics Inc. filed an 8-K report detailing a material definitive agreement. The filing includes exhibits such as the agreement itself (EX-10.1) and other related documents, indicating a significant business development for the company.
Why It Matters
This filing signifies a new, potentially impactful business arrangement for Soleno Therapeutics, which could influence its future operations and market position.
Risk Assessment
Risk Level: medium — The filing of a material definitive agreement suggests a significant business event, but the specific nature and impact are not detailed, requiring further investigation.
Key Numbers
- 0001193125-26-142911 — SEC Accession Number (Unique identifier for this specific SEC filing)
- 2026-04-05 — Period of Report (The date range the report covers)
Key Players & Entities
- Soleno Therapeutics Inc. (company) — Filer of the 8-K report
- 0001484565 (company) — CIK number for Soleno Therapeutics Inc.
- 2026-04-06 (date) — Filing date of the 8-K report
- EX-10.1 (document) — Exhibit containing a material definitive agreement
FAQ
What is the nature of the material definitive agreement filed by Soleno Therapeutics?
The filing does not specify the exact nature of the material definitive agreement, but it is listed under Item 1.01, indicating a significant contractual arrangement.
When was this 8-K filing accepted by the SEC?
The 8-K filing was accepted by the SEC on April 6, 2026, at 07:46:57.
What are the key exhibits included in this filing?
Key exhibits include EX-2.1, EX-10.1 (Material Definitive Agreement), and EX-99.1, along with XBRL documents.
What is Soleno Therapeutics' business address?
Soleno Therapeutics' business address is 100 MARINE PARKWAY, SUITE 400, REDWOOD CITY CA 94065.
What is the CIK number for Soleno Therapeutics Inc.?
The CIK number for Soleno Therapeutics Inc. is 0001484565.
From the Filing
EDGAR Filing Documents for 0001193125-26-142911 This page uses Javascript. Your browser either doesn't support Javascript or you have it turned off. To see this page as it is meant to appear please use a Javascript enabled browser. SEC.gov EDGAR Latest Filings Filings search tools Filing Detail SEC Home » Company Search » Current Page Form 8-K - Current report: SEC Accession No. 0001193125-26-142911 Filing Date 2026-04-06 Accepted 2026-04-06 07:46:57 Documents 14 Period of Report 2026-04-05 Items Item 1.01: Entry into a Material Definitive Agreement Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits Interactive Data Document Format Files Seq Description Document Type Size 1 8-K d142985d8k.htm iXBRL 8-K 61308 2 EX-2.1 d142985dex21.htm EX-2.1 631020 3 EX-10.1 d142985dex101.htm EX-10.1 66676 4 EX-99.1 d142985dex991.htm EX-99.1 34861 Complete submission text file 0001193125-26-142911.txt 1114876 Data Files Seq Description Document Type Size 5 XBRL TAXONOMY EXTENSION SCHEMA slno-20260405.xsd EX-101.SCH 2847 6 XBRL TAXONOMY EXTENSION LABEL LINKBASE slno-20260405_lab.xml EX-101.LAB 17991 7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE slno-20260405_pre.xml EX-101.PRE 11258 18 EXTRACTED XBRL INSTANCE DOCUMENT d142985d8k_htm.xml XML 3667 Mailing Address 100 MARINE PARKWAY, SUITE 400 REDWOOD CITY CA 94065 Business Address 100 MARINE PARKWAY, SUITE 400 REDWOOD CITY CA 94065 650-213-8444 SOLENO THERAPEUTICS INC (Filer) CIK : 0001484565 (see all company filings) EIN. : 770523891 | State of Incorp.: DE | Fiscal Year End: 1231 Type: 8-K | Act: 34 | File No.: 001-36593 | Film No.: 26839573 SIC : 2834 Pharmaceutical Preparations (CF Office: 03 Life Sciences)